Jing Yang

Jing Yang

Auto-generated profile, based on publicly available information

Jing Yang

Medical Innovation Research Department of Chinese PLA General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
JYJing Yang
Jing Yang
ZJZhilong Jia
Zhilong Jia
XSXinyu Song
Xinyu Song
JSJinlong Shi
Jinlong Shi
XWXiaoreng Wang
Xiaoreng Wang
KHKunlun He
Kunlun He
Ascending to high-altitude by non-high-altitude natives is a well-suited model for studying acclimatization to extreme environments. Acute mountain sickness (AMS) is frequently experienced by visitors. The diagnosis of AMS mainly depends on a self-questionnaire, revealing the need for reliable biomarkers for AMS. Here, we profiled 22 AMS symptom phenotypes, 65 clinical indexes, and plasma proteomic profiles of AMS via a combination of proximity extension assay and multiple reaction monitoring of a longitudinal cohort of 53 individuals. We quantified 1069 proteins and validated 102 proteins. Via differential analysis, machine learning, and functional association analyses. We found and validated that RET played an important role in the pathogenesis of AMS. With high-accuracies (AUCs > 0.9) of XGBoost-based models, we prioritized ADAM15, PHGDH, and TRAF2 as protective, predictive, and diagnostic biomarkers, respectively. Our findings shed light on the precision medicine for AMS and the understanding of acclimatization to high-altitude environments.

18 March 2016 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
ACAndrew L. Coveler
Andrew L. Coveler
AKAndrew H. Ko
Andrew H. Ko
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
DHDaniel Douglas Von Hoff
Daniel Douglas Von Hoff
CBCarlos Becerra
Carlos Becerra
BWBrian Wolpin
Brian Wolpin

30 August 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CACletus A. Arciero
Cletus A. Arciero
JYJing Yang
Jing Yang
LPLimin Peng
Limin Peng
KWKevin C. Ward
Kevin C. Ward
RORuth O’regan
Ruth O’regan
XLXiaoxian Li
Xiaoxian Li

30 September 2010 in Blood
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
YLYongsheng Li
Yongsheng Li
MNMichael A. Nardi
Michael A. Nardi
SDSuying Dang
Suying Dang
JYJing Yang
Jing Yang
Thomas WisniewskiThomas Wisniewski
Thomas Wisniewski
Patients with HIV-1 immune-related thrombocytopenia have a unique antibody (Ab) against integrin GPIIIa49-66 capable of inducing oxidative platelet fragmentation via Ab activation of platelet nicotinamide adenine dinucleotide phosphate oxidase and 12-lipoxygenase releasing reactive oxygen species. Using a phage display single-chain antibody (scFv) library, we developed a novel human monoclonal scFv Ab against GPIIIa49-66 (named A11) capable of inducing fragmentation of activated platelets. In this study, we investigated the in vivo use of A11. We show that A11 does not induce significant thrombocytopenia or inhibit platelet function. A11 can prevent the cessation of carotid artery flow produced by induced artery injury and dissolve the induced thrombus 2 hours after cessation of blood flow. In addition, A11 can prevent, as well as ameliorate, murine middle cerebral artery stroke, without thrombocytopenia or brain hemorrhage. To further optimize the antithrombotic activity of A11, we produced a bifunctional A11-plasminogen first kringle agent (SLK), which homes to newly deposited fibrin strands within and surrounding the platelet thrombus, reducing effects on nonactivated circulating platelets. Indeed, SLK is able to completely reopen occluded carotid vessels 4 hours after cessation of blood flow, whereas A11 had no effect at 4 hours. Thus, a new antithrombotic agent was developed for platelet thrombus clearance.

1 November 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
XQXianxin Qiu
Xianxin Qiu
JGJing Gao
Jing Gao
JYJing Yang
Jing Yang
JHJiyi Hu
Jiyi Hu
WHWeixu Hu
Weixu Hu
LKLin Kong
Lin Kong
Perfusion MR prior to radiotherapy is a strong predictor of survival in high-grade gliomas after proton and carbon ion radiotherapy Xianxin Qiu, Jing Gao, Jing Yang, Jiyi Hu, Weixu Hu, Xiaoyong Zhang, Jiade J. Lu, Lin Kong

1 September 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
JBJ. Brahmer
J. Brahmer
DRD. Rodríguez-Abreu
D. Rodríguez-Abreu
Andrew G. RobinsonAndrew G. Robinson
Andrew G. Robinson
RHRina Hui
Rina Hui
TCT. Csőszi
T. Csőszi
MRM. Reck
M. Reck